摘要
全身性硬化症合併間質性肺病往往會對病患日常生活帶來極大的影響。新的藥物如Tocilizumab以及Nintedanib在臨床試驗成功，也對病患帶來新的曙光。
參考文獻
Hoffmann-Vold A-M, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021;80:219-27.
Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. New Engl J Medicine 2006;354:2655-66.
Goldin J, Elashoff R, Kim HJ, et al. Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo Findings From the Scleroderma Lung Study. Chest 2009;136:1333-40.
Roth MD, Tseng C-H, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma‐related interstitial lung disease. Arthritis Rheumatism 2011;63:2797-808.
Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheumatism 2006;54:3962-70.
延伸閱讀
- 張恆鴻、許吟姿、陳雅吟（1994）。中西藥並用治療進行性系統性硬皮病合併肺間質病變－病例報告。中醫藥雜誌，5(3)，209-215。https://doi.org/10.6940/JCM.199409_5(3).06
- Tseng, C. C., Wu, C. C., Lin, M. C., & Hsieh, M. J. (2004). 結節性硬化症合併反覆性氣胸及肺移植－一個案例報告. 胸腔醫學, 19(2), 145-151. https://doi.org/10.29806/TM.200404.0010
- 曹唐義、曾暉華、陳春香、杜炎昌、藍功堯（1986）。肺硬化性血管瘤之免疫組織化學－病例報告及文獻回顧。Journal of Medical Sciences，7(3)，189-196。https://www.airitilibrary.com/Article/Detail?DocID=10114564-198611-201404230015-201404230015-189-196
- Chang, K. W., Chen, I. H., & Lin, P. Y. (2018). 【論文摘要】肺腺癌併發肺炎與敗血性休克患者之物理治療介入效果：個案報告. 物理治療, 43(4), 310-310. https://doi.org/10.6215/FJPT.201812.P01
- 陳卉溱（2020）。慢性阻塞性肺疾病惡化的治療。嘉基藥訊，(150)，1-4。https://www.airitilibrary.com/Article/Detail?DocID=a0000124-202011-202110060010-202110060010-1-4